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Résumé en
anglais
An assay prototype designed to detect and quantify total hepatitis C virus [HCV] core
antigen (HCV core Ag) protein in serum and plasma in the presence or absence of
anti-HCV antibodies has been recently developed by Ortho-Clinical Diagnostics. The
aim of the study was to evaluate the sensitivity, specificity, and reproducibility of the
Total HCV core Ag assay in comparison with two quantitative assays for HCV RNA:
Quantiplex HCV RNA 2.0 (bDNA v2.0) or Versant HCV RNA 3.0 (bDNA v3.0) assays
and the Cobas Amplicor HCV Monitor version 2.0 (HCM v2.0) test. We have studied
samples of a well-characterized panel and samples from patients with chronic
hepatitis C treated with interferon alone or with ribavirin. We have also compared
the kinetics of HCV core Ag and HCV RNA in the follow-up of treated patients. The
HCV core Ag assay exhibited linear behavior across samples from different
genotypes. The coefficients of variation for intra- and interassay performance were
5.11 and 9.95%, respectively. The specificity of the assay tested in blood donors was
99.5%. Samples from HCV-infected patients showed that the correlation between the
HCV core Ag and the two HCV RNA quantitative assays (bDNA and HCM v2.0) was
0.8 and 0.7, respectively. This correlation was maintained across different genotypes
of HCV (r(2) = 0.64 to 0.94). Baseline HCV core Ag values were significantly lower in
sustained responders to interferon (IFN) than in other groups of patients (5.31
log(10) [10(4) pg/ml] versus 5.99 log(10) [10(4) pg/ml]; P < 0.001). In patients
treated with IFN or combination therapy, we found an association between a
decrease of more than 2 log IU/ml in viral load, undetectable HCV core Ag, and
sustained response. Among sustained responders to IFN alone or combination
therapy and among relapsers after IFN alone, 84 out of 101 (83.2%) had
undetectable HCV core Ag, and 76 out of 96 (79.2%) had a viral load decrease of
>/=2 log IU/ml, after 1 month of treatment. In conclusion, the Total HCV core Ag
assay is a new useful test for the detection of HCV viremia and the monitoring of
patients treated with IFN alone or in combination with ribavirin.
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